Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Biomimetic antimicrobial peptide inspired by insects to combat multi-drug-resistant Acinetobacter baumannii

Obiettivo

OMN6 is a synthetic cyclic peptide developed to treat infections caused by multidrug resistant A. baumannii, a WHO critical priority pathogen linked to high mortality. After a clean Phase 1 and an ongoing Phase 2, PEPTAMR moves OMN6 toward late clinical development with the goal of delivering a regulatory-ready Phase 3 package
The project will expand clinical data collection across Europe, complete the preclinical work needed to justify dosing and indications, run a healthy-volunteer lung penetration study, and finalise a stable, scalable clinical formulation ready for manufacturing. A companion diagnostic roadmap will be prepared to help clinicians identify patients who can benefit most.
Led by OMN with VIV, MUV, NKUA and ECR, PEPTAMR combines industry and academic strengths to produce the assays, models and clinical evidence that will enable licensing and broad hospital use. The ultimate aim is to provide hospitals with a safe, effective, and practical therapy for a deadly, hard to treat pathogen.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-RIA - HORIZON Research and Innovation Actions

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-HLTH-2025-01

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

OMNIX MEDICAL LTD
Contributo netto dell'UE
€ 4 943 800,00
Indirizzo
RACAH 1
9270401 JERUSALEM
Israele
PMI
Sì
Tipo di attività
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Collegamenti
Costo totale
€ 4 943 800,00

Partecipanti (4)